151 related articles for article (PubMed ID: 17369114)
1. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars.
Borody TJ; Bilkey S; Wettstein AR; Leis S; Pang G; Tye S
Dig Liver Dis; 2007 May; 39(5):438-44. PubMed ID: 17369114
[TBL] [Abstract][Full Text] [Related]
2. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.
Selby W; Pavli P; Crotty B; Florin T; Radford-Smith G; Gibson P; Mitchell B; Connell W; Read R; Merrett M; Ee H; Hetzel D;
Gastroenterology; 2007 Jun; 132(7):2313-9. PubMed ID: 17570206
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure?
Borody TJ; Leis S; Warren EF; Surace R
Dig Liver Dis; 2002 Jan; 34(1):29-38. PubMed ID: 11926571
[TBL] [Abstract][Full Text] [Related]
4. Australian Crohn's antibiotic study opens new horizons.
Gitlin L; Biesecker J
Gastroenterology; 2007 Nov; 133(5):1743-4; author reply 1745-6. PubMed ID: 17983826
[No Abstract] [Full Text] [Related]
5. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion.
Clancy R; Ren Z; Turton J; Pang G; Wettstein A
Dig Liver Dis; 2007 May; 39(5):445-51. PubMed ID: 17317344
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium avium subspecies paratuberculosis and Crohn's disease granulomas.
Toracchio S; El-Zimaity HM; Urmacher C; Katz S; Graham DY
Scand J Gastroenterol; 2008; 43(9):1108-11. PubMed ID: 18609156
[TBL] [Abstract][Full Text] [Related]
7. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease.
Shafran I; Kugler L; El-Zaatari FA; Naser SA; Sandoval J
Dig Liver Dis; 2002 Jan; 34(1):22-8. PubMed ID: 11930899
[TBL] [Abstract][Full Text] [Related]
8. Antimycobacterial therapy in Crohn's disease: game over?
Peyrin-Biroulet L; Neut C; Colombel JF
Gastroenterology; 2007 Jun; 132(7):2594-8. PubMed ID: 17570230
[No Abstract] [Full Text] [Related]
9. Presence and characterization of Mycobacterium avium subspecies paratuberculosis from clinical and suspected cases of Crohn's disease and in the healthy human population in India.
Singh AV; Singh SV; Makharia GK; Singh PK; Sohal JS
Int J Infect Dis; 2008 Mar; 12(2):190-7. PubMed ID: 17913536
[TBL] [Abstract][Full Text] [Related]
10. Importance of the Australian Crohn's disease antibiotic study.
Chamberlin W
Gastroenterology; 2007 Nov; 133(5):1744-5; author reply 1745-6. PubMed ID: 17983827
[No Abstract] [Full Text] [Related]
11. The use of antimycobacterial agents in Crohn's disease.
Thayer WR
J Clin Gastroenterol; 1992 Jul; 15(1):5-7. PubMed ID: 1323594
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications.
Savarino E; Bertani L; Ceccarelli L; Bodini G; Zingone F; Buda A; Facchin S; Lorenzon G; Marchi S; Marabotto E; De Bortoli N; Savarino V; Costa F; Blandizzi C
Expert Opin Biol Ther; 2019 Feb; 19(2):79-88. PubMed ID: 30574820
[TBL] [Abstract][Full Text] [Related]
13. [Follow up of Crohn's disease under therapy with hydro-MRI].
Ganten M; Encke J; Flosdorff P; Grüber-Hoffmann B; Erb G; Hansmann J
Radiologe; 2003 Jan; 43(1):26-33. PubMed ID: 12552372
[TBL] [Abstract][Full Text] [Related]
14. A case-control study of drinking water and dairy products in Crohn's Disease--further investigation of the possible role of Mycobacterium avium paratuberculosis.
Abubakar I; Myhill DJ; Hart AR; Lake IR; Harvey I; Rhodes JM; Robinson R; Lobo AJ; Probert CS; Hunter PR
Am J Epidemiol; 2007 Apr; 165(7):776-83. PubMed ID: 17237136
[TBL] [Abstract][Full Text] [Related]
15. The evidence for Mycobacterium paratuberculosis in Crohn's disease.
Behr MA; Kapur V
Curr Opin Gastroenterol; 2008 Jan; 24(1):17-21. PubMed ID: 18043227
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
Plamondon S; Ng SC; Kamm MA
Aliment Pharmacol Ther; 2007 Mar; 25(5):557-67. PubMed ID: 17305756
[TBL] [Abstract][Full Text] [Related]
17. The Australian antibiotic trial in Crohn's disease: alternative conclusions from the same study.
Kuenstner JT
Gastroenterology; 2007 Nov; 133(5):1742-3; author reply 1745-6. PubMed ID: 17983824
[No Abstract] [Full Text] [Related]
18. Oral butyrate for mildly to moderately active Crohn's disease.
Di Sabatino A; Morera R; Ciccocioppo R; Cazzola P; Gotti S; Tinozzi FP; Tinozzi S; Corazza GR
Aliment Pharmacol Ther; 2005 Nov; 22(9):789-94. PubMed ID: 16225487
[TBL] [Abstract][Full Text] [Related]
19. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how.
Prantera C; Scribano ML
Curr Opin Gastroenterol; 2009 Jul; 25(4):329-33. PubMed ID: 19444096
[TBL] [Abstract][Full Text] [Related]
20. Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease.
Inoue S; Nakase H; Matsuura M; Ueno S; Uza N; Kitamura H; Mikami S; Tamaki H; Kasahara K; Chiba T
J Gastroenterol Hepatol; 2007 Jul; 22(7):984-8. PubMed ID: 17608842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
